Leponex

Clozapine, the active ingredient in Leponex, is an atypical antipsychotic presented as a tablet for oral use. It is indicated for treatment‑resistant schizophrenia and schizoaffective disorder, providing symptom control in patients who have not responded adequately to other antipsychotics.

GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets.

Leponex (clozapine) is used in the management of severe psychotic disorders that are resistant to standard therapy.

Treatment‑resistant schizophrenia: reduces psychotic symptoms in patients who have not responded to at least two other antipsychotics. Schizoaffective disorder: helps control both mood and psychotic components when other treatments are insufficient. Persistent psychosis: provides symptom relief in chronic psychotic states unresponsive to other agents.

Leponex may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Constipation - Excessive salivation - Weight gain - Dizziness or light‑headedness - Tachycardia

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count) - Myocarditis or cardiomyopathy - Seizures, especially at higher plasma levels - Severe orthostatic hypotension - Neuroleptic malignant syndrome - Pulmonary embolism

Leponex requires careful monitoring and patient education.

Monitor blood counts: perform regular complete blood count with differential to detect agranulocytosis. Assess cardiac function: evaluate for myocarditis signs, especially early in treatment. Avoid abrupt discontinuation: taper under medical supervision to reduce relapse risk. Use caution in patients with seizures: monitor for seizure activity and adjust therapy as needed. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Clozapine interacts with several medicines that may alter its safety or effectiveness.

Major Interactions (Avoid): - Concomitant use with carbamazepine: may reduce clozapine levels and increase seizure risk. - Co‑administration with fluvoxamine: can markedly increase clozapine plasma concentrations. - Combination with other myelosuppressive agents: heightened risk of agranulocytosis.

Moderate Interactions (Monitor Closely): - Smoking induces CYP1A2, potentially lowering clozapine levels; dose adjustment may be needed. - Use with benzodiazepines: may enhance sedation and respiratory depression. - Concurrent use of QT‑prolonging drugs: monitor ECG for arrhythmia risk.